Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Has CV19 kept the burn so loe?
View:
Post by SouthernTierTom on Dec 23, 2021 5:17pm

Has CV19 kept the burn so loe?

I was estimating that there was about 3.5M CAD in the kitty...

Seems a bit of a catch 22, if trial activity ramps up s we hope....so will burn.

We had about 1.6M or so in the kitty tha last time we "raised", but we are now deep into the phase 2 experience that includes operations here in the US.

I would not at all be unhappy with a "raise"...but at what price?

Thoughts,

Tuckey?...Macer? ; - )
Comment by enriquesuave on Dec 23, 2021 5:45pm
When data will hopefully soon conclusively place TLD-1433 as the (or one of the) top contenders as a new Gold Standard for BCG UnResponsive NMIBC, then SP may surely rise to levels never before reached.  At that time point, excercise of warrants and/or a raise would be appropriate.  We all know it's coming soon enough and the company has more than enough cash to get us there.   ...more  
Comment by skier59 on Dec 23, 2021 7:10pm
enriquesuave, always enjoy reading your posts ! TractorTom, always wondered how much they pay You, for these posts ? Yes, you were right on that last disgusting raise. Your Boss, succeeded and got Us cheap. Doesn't mean your Gang, will get us the next time. Seems we have a Safe House, and fantastic results so far !.....more to come ?.....I'm feeling good, providing the procedure is ...more  
Comment by skier59 on Dec 23, 2021 8:44pm
I have no idea how, that last line got included in my post ???
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250